NCT05023928 is a Phase 1 clinical trial of Tumor antigen-sensitized DC vaccine in Carcinoma, sponsored by Sichuan University.

Who is sponsoring NCT05023928?

NCT05023928 is sponsored by Sichuan University.

What drugs are being tested in NCT05023928?

Interventions in NCT05023928: Tumor antigen-sensitized DC vaccine.

What condition does NCT05023928 study?

NCT05023928 studies Carcinoma, Esophagus Cancer.

Is NCT05023928 still recruiting?

NCT05023928 is currently completed. Last updated 12 March 2025.

Last reviewed 2025-03-12 · How we verify

NCT05023928

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer

Completed Phase 1 Last updated 12 March 2025

What this trial tests

Phase 1 trial testing Tumor antigen-sensitized DC vaccine in Carcinoma in 25 participants. Completed in 30 October 2024.

Timeline

1 September 2021

Primary endpoint
1 October 2023

30 October 2024

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 September 2021
Primary completion	1 October 2023
Estimated completion	30 October 2024
Sites	1 location across China

Drugs / interventions tested

Tumor antigen-sensitized DC vaccine — full drug profile →

Conditions studied

Carcinoma — all drugs for Carcinoma →
Esophagus Cancer — all drugs for Esophagus Cancer →

Sponsor

Sichuan University

Who can join

Adults 18 to 75, any sex, with Carcinoma or Esophagus Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Neoantigen cancer vaccines: a new star on the horizon.
Li X, You J, Hong L, Liu W, et al · · 2023 · cited 31× · PMID 38164734 · DOI 10.20892/j.issn.2095-3941.2023.0395
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876
Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens.
Hao Q, Long Y, Yang Y, Deng Y, et al · · 2024 · cited 11× · PMID 39066355 · DOI 10.3390/vaccines12070717
Research and Clinical Progress of Therapeutic Tumor Vaccines.
Dong C, Li Z, Tan D, Sun H, et al · · 2025 · cited 3× · PMID 40733649 · DOI 10.3390/vaccines13070672
Advances in neoantigen-based immunotherapy for head and neck squamous cell carcinoma: a comprehensive review.
Jiang M, Li J, Wei J, Yang X, et al · · 2025 · PMID 40444094 · DOI 10.3389/fonc.2025.1593048

Verify or expand the search:

Other recruiting trials for Carcinoma

Currently open trials in the same condition.

NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
NCT06969534 — Safety and Efficacy of Pucotenlimab in pLECC · Phase 2 · recruiting
NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
NCT07470827 — Evaluation of 'WAYMED Endo CL CS' for Automated Detection and Diagnosis of Colorectal Adenoma and Non-Adenoma Lesions · active not recruiting
NCT06317311 — A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recu · Phase 2 · active not recruiting

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05023928 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 12 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05023928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing